These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 20180377

  • 1. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

  • 2. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP.
    Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
    [Abstract] [Full Text] [Related]

  • 4. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS.
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [Abstract] [Full Text] [Related]

  • 5. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 7. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [Abstract] [Full Text] [Related]

  • 9. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 10. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 11. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.
    Am J Gastroenterol; 2000 Nov 01; 95(11):3189-94. PubMed ID: 11095340
    [Abstract] [Full Text] [Related]

  • 12. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 01; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 13. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684
    [Abstract] [Full Text] [Related]

  • 14. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 01; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 15. Short-term study of infliximab treatment for Crohn's disease in China.
    Zheng JJ, Zhi P, Wang YM, Zhu F, Gu W, Xing YC, Zhou CL, Shen BW.
    J Dig Dis; 2011 Apr 01; 12(2):105-9. PubMed ID: 21401895
    [Abstract] [Full Text] [Related]

  • 16. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 17. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 01; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 18. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL, García-Paredes J, Cruz Santamaria DM, Lana R, Ramírez Fernández E, Rodríguez Asteaga E, Díaz-Rubio M.
    Rev Esp Enferm Dig; 2002 May 01; 94(5):269-79. PubMed ID: 12474335
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ.
    Am J Gastroenterol; 2001 Mar 01; 96(3):722-9. PubMed ID: 11280541
    [Abstract] [Full Text] [Related]

  • 20. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 01; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.